Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies

Expert Opinion on Drug Safety

Volumn 2, Issue 5, 2003, Pages 467-473

  Dereure, O ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

anti TNF ; monoclonal antibodies; side effects; skin; tyrosine kinase inhibitors

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; ENZYME INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN;

CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; HUMAN; REVIEW; SKIN DISEASE;

ANTIBODIES, MONOCLONAL; CYTOKINES; ENZYME INHIBITORS; HUMANS; PROTEIN-TYROSINE KINASES; RECEPTORS, CYTOKINE; RECOMBINANT PROTEINS; SKIN DISEASES;

EID: 2142679300     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.5.467     Document Type: Review

References (37)

1. MARKHAM A, LAMB HM: Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs (2000) 59:1341-1359. (Pubitemid 30410148)
2. MEASE PJ: Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann. Rheum. Dis. (2002) 61:298-304. (Pubitemid 34257738)
3. SCHOPF RE, AUST H, KNOP J: Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor-?, infliximab. J. Am. Acad. Dermatol. (2002) 46:886-891.
4. CHAN AT, CLEEVE V, DAYMOND TJ: Necrotizing fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad. Med. J. (2002) 78:47-48. (Pubitemid 34074917)
5. KENT PD, DAVIS JM III, DAVIS MD, MATTESON EL: Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum. (2002) 46:2257-2258.
6. MCCAIN ME, QUINET RJ, DAVIS WE: Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) (2002) 41:116-117. (Pubitemid 34537935)
7. SHIN DM, DONATO NJ, PEREZ-SOLER R et al.: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. (2001) 7:1204-1213. (Pubitemid 32708671)
8. BUSAM KJ, CAPODIECI P, MOTZER R, KIEHN T, PHELAN D, HALPERN AC: Cutaneous side effects in cancer patients treated with the anti-epidermal growth factor receptor antibody C225. Br. J. Dermatol. (2001) 144:1169-1176. (Pubitemid 34204207)
9. MENDELSOHN J: Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. (2002) 20(18 Suppl.):S1-S13.
10. KIMYAI-ASADI A, JIH MH: Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch. Dermatol. (2002) 138:129-131. (Pubitemid 34056253)
11. NEEDLE MN: Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin. Oncol. (2002) 29(Suppl. 14):55-60. (Pubitemid 35191047)
12. HERBST RS, HONG WK: IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin. Oncol. (2002) 29(Suppl. 14):18-30. (Pubitemid 35191043)
13. BOUCHER KW, DAVIDSON K, MIRAKHUR B, GOLDBERG J, HEYMANN WR: Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J. Am. Acad. Dermatol. (2002) 47:632-633.
14. MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapse indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16:2825-2833. (Pubitemid 28363048)
15. TOBINAI K, KOBAYASHI Y, NARABAYASHI M et al.: Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann. Oncol. (1998) 9:527-534. (Pubitemid 28270641)
16. TOBINAI K: Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan. Cancer Chemother. Pharmacol. (2001) 48(Suppl. 1):S85-S90. (Pubitemid 33738379)
17. DEREURE O, NAVARRO R, ROSSI JF, GUILHOU JJ: Rituximab-induced vasculitis. Dermatology (2001) 203:83-84.
18. LUNDIN J, KIMBY E, BJORKHOLM M et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood (2002) 100:768-773. (Pubitemid 34832599)
19. MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385-390. (Pubitemid 30487495)
20. MURPHY FT, ENZENAUER RJ, BATTAFARANO DF, DAVID-BAJAR K: Etanercept-associated injection-site reactions. Arch. Dermatol. (2000) 136:556-557.
21. ZELTSER R, VALLE L, TANCK C, HOLYST MM, RITCHLIN C, GASPARI AA: Clinical, histological and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor-α receptor: Fc fusion protein. Arch. Dermatol. (2001) 137:893-899. (Pubitemid 32641648)
22. BRION PH, MITTAL-HENKLE A, KALUNIAN KC: Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann. Intern. Med. (1999) 131:634. (Pubitemid 29494103)
23. SOLIOTIS F, GLOVER M, JAWAD AS: Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann. Rheum. Dis. (2002) 61:850-851.
24. BLEUMINK GS, TER BORG EJ, RAMSELAAR CG, CH STRICKER BH: Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) (2001) 40:1317-1319. (Pubitemid 33100103)
25. SHAKOOR N, MICHALSKA M, HARRIS CA, BLOCK JA: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 359:579-580. (Pubitemid 34178442)
26. SMITH KJ, SKELTON HG: Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor α receptor IgG1-Fc fusion complex therapy. J. Am. Acad. Dermatol. (2001) 45:953-956. (Pubitemid 33096643)
27. FIGGITT DP, LAMB HM, GOA KL: Denileukin diftitox. Am. J. Clin. Dermatol. (2000) 1:67-72.
28. SAVAGE DG, ANTMAN KH: Imatinib mesylate-a new oral targeted therapy. N. Engl. J. Med. (2002) 346:683-693. (Pubitemid 34815874)
29. DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344:1031-1037. (Pubitemid 32267972)
30. JOENSUU H, ROBERTS P, SARLOMO-RIKALA M et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. (2001) 344:1052-1056. (Pubitemid 32267975)
31. BROUARD MC, PRINS C, MACH-PASCUAL S, SAURAT JH: Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology (2001) 203:57-59. (Pubitemid 32830533)
32. LIM DS, MUIR J: Oral lichenoid reaction to imatinib (STI571, Gleevec). Dermatology (2002) 205:169-171.
33. KONSTANTOPOULOS K, PAPADOGIANNI A, DIMOPOULOU M, KOURELIS C, MELETIS J: Pityriasis rosea associated with imatinib (STI571, Gleevec). Dermatology (2002) 205:172-173.
34. VALEYRIE L, BASTUJI-GARIN S, REVUZ J et al.: Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J. Am. Acad. Dermatol. (2003) 48:201-206. (Pubitemid 36232317)
35. ALBANELL J, ROJO F, AVERBUCH S et al.: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. (2002) 20:110-124. (Pubitemid 34032602)
36. BASELGA J, RISCHIN D, RANSON M, et al.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. (2002) 20:4292-4302. (Pubitemid 35266289)
37. HIDALGO M, SIU LL, NEMUNAITIS J et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. (2001) 19:3267-3279. (Pubitemid 32591445)